Elevated Plasma B-Type Natriuretic Peptide Concentrations Directly Inhibit Circulating Neprilysin Activity in Heart Failure

JACC: Heart Failure

Volumn 3, Issue 8, 2015, Pages 629-636

  Vodovar, Nicolas ^a,b   Séronde, Marie France ^a,c   Laribi, Said ^a,d   Gayat, Etienne ^a,d,e   Lassus, Johan ^f   Januzzi, James L ^g   Boukef, Riadh ^h   Nouira, Semir ^h   Manivet, Philippe ^a,b,d   Samuel, Jane Lise ^a,b,d   Logeart, Damien ^a,b,d,i   Cohen Solal, Alain ^a,b,d,i   Richards, A Mark ^j,k   Launay, Jean Marie ^a,b,d   Mebazaa, Alexandre ^a,c,d,e  

^a APHP   (France)

^b DHU Fire   (France)

^c UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^d HÔPITAL LARIBOISIÈRE   (France)

^e DHU Neurovasc   (France)

^f HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h FATTOUMA BOURGUIBA UNIVERSITY HOSPITAL   (Tunisia)

ⁱ UNIVERSITÉ PARIS DESCARTES   (France)

^j UNIVERSITY OF OTAGO   (New Zealand)

^k NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

more..

Author keywords

BNP; BNP mediated neprilysin inhibition; Heart failure; Neprilysin; Substance P

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; MEMBRANE METALLOENDOPEPTIDASE; SUBSTANCE P; BIOLOGICAL MARKER; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ACUTE HEART FAILURE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATIONAL STUDY; DYSPNEA; EMERGENCY WARD; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME KINETICS; HEART FAILURE; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; REFERENCE VALUE; SURVIVAL RATE;

BIOMARKERS; HEART FAILURE; HUMANS; IN VITRO TECHNIQUES; NATRIURETIC PEPTIDE, BRAIN; NEPRILYSIN; PEPTIDE FRAGMENTS; PROGNOSIS; REFERENCE VALUES; SURVIVAL RATE;

EID: 84939424765     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2015.03.011     Document Type: Article

References (37)

1. McMurray J.J., Adamopoulos S., Anker S.D., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Eur Heart J 2012, 33:1787-1847.
2. Yancy C.W., Jessup M., Bozkurt B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013, 62:e147-e239.
3. Luckenbill K.N., Christenson R.H., Jaffe A.S., et al. Cross-reactivity of BNP, NT-proBNP, and proBNP in commercial BNP and NT-proBNP assays: preliminary observations from the IFCC Committee for Standardization of Markers of Cardiac Damage. Clin Chem 2008, 54:619-621.
4. Hawkridge A.M., Heublein D.M., Bergen H.R., Cataliotti A., Burnett J.C., Muddiman D.C. Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc Natl Acad Sci U S A 2005, 102:17442-17447.
5. Miller W.L., Phelps M.A., Wood C.M., et al. Comparison of mass spectrometry and clinical assay measurements of circulating fragments of B-type natriuretic peptide in patients with chronic heart failure. Circ Heart Fail 2011, 4:355-360.
6. Nishikimi T., Okamoto H., Nakamura M., et al. Direct immunochemiluminescent assay for proBNP and total BNP in human plasma proBNP and total BNP levels in normal and heart failure. PLoS One 2013, 8:e53233.
7. Levin E.R., Gardner D.G., Samson W.K. Natriuretic peptides. N Engl J Med 1998, 339:321-328.
8. Tamura N., Ogawa Y., Chusho H., et al. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci U S A 2000, 97:4239-4244.
9. Silberbach M., Roberts C.T. Natriuretic peptide signalling: molecular and cellular pathways to growth regulation. Cell Signal 2001, 13:221-231.
10. Rubattu S., Sciarretta S., Valenti V., Stanzione R., Volpe M. Natriuretic peptides: an update on bioactivity, potential therapeutic use, and implication in cardiovascular diseases. Am J Hypertens 2008, 21:733-741.
11. Kuhn M., Volker K., Schwarz K., et al. The natriuretic peptide/guanylyl cyclase-a system functions as a stress-responsive regulator of angiogenesis in mice. J Clin Invest 2009, 119:2019-2030.
12. Richards A.M., Wittert G.A., Espiner E.A., Yandle T.G., Ikram H., Frampton C. Effect of inhibition of endopeptidase 24.11 on responses to angiotensin II in human volunteers. Circ Res 1992, 71:1501-1507.
13. Seymour A.A., Abboa-Offei B.E., Smith P.L., Mathers P.D., Asaad M.M., Rogers W.L. Potentiation of natriuretic peptides by neutral endopeptidase inhibitors. Clin Exp Pharmacol Physiol 1995, 22:63-69.
14. O'Connor C.M., Starling R.C., Hernandez A.F., et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011, 365:32-43.
15. Efficacy and Safety of Ularitide for the Treatment of Acute Decompensated Heart Failure (TRUE-AHF). Available at: . Accessed June 2015. https://clinicaltrials.gov/ct2/show/NCT01661634.
16. Wei C.M., Kim C.H., Miller V.M., Burnett J.C. Vasonatrin peptide: a unique synthetic natriuretic and vasorelaxing peptide. J Clin Invest 1993, 92:2048-2052.
17. Lisy O., Huntley B.K., McCormick D.J., Kurlansky P.A., Burnett J.C. Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP. J Am Coll Cardiol 2008, 52:60-68.
18. Packer M., Califf R.M., Konstam M.A., et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2002, 106:920-926.
19. McMurray J.J., Packer M., Desai A.S., et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014, 371:993-1004.
20. Dalzell J.R., Seed A., Berry C., et al. Effects of neutral endopeptidase (neprilysin) inhibition on the response to other vasoactive peptides in small human resistance arteries: studies with thiorphan and omapatrilat. Cardiovasc Ther 2014, 32:13-18.
21. Mangiafico S., Costello-Boerrigter L.C., Andersen I.A., Cataliotti A., Burnett J.C. Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. Eur Heart J 2013, 34:886-893c.
22. Pankow K., Wang Y., Gembardt F., et al. Successive action of meprin A and neprilysin catabolizes B-type natriuretic peptide. Circ Res 2007, 101:875-882.
23. Kenny A.J., Bourne A., Ingram J. Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11. Biochem J 1993, 291(Pt 1):83-88.
24. Watanabe Y., Nakajima K., Shimamori Y., Fujimoto Y. Comparison of the hydrolysis of the three types of natriuretic peptides by human kidney neutral endopeptidase 24.11. Biochem Mol Med 1997, 61:47-51.
25. Smith M.W., Espiner E.A., Yandle T.G., Charles C.J., Richards A.M. Delayed metabolism of human brain natriuretic peptide reflects resistance to neutral endopeptidase. J Endocrinol 2000, 167:239-246.
26. Dickey D.M., Potter L.R. Human B-type natriuretic peptide is not degraded by meprin A. Biochem Pharmacol 2010, 80:1007-1011.
27. Pankow K., Schwiebs A., Becker M., Siems W.E., Krause G., Walther T. Structural substrate conditions required for neutral endopeptidase-mediated natriuretic peptide degradation. J Mol Biol 2009, 393:496-503.
28. Belenky A., Smith A., Zhang B., et al. The effect of class-specific protease inhibitors on the stabilization of B-type natriuretic peptide in human plasma. Clin Chim Acta 2004, 340:163-172.
29. Dickey D.M., Potter L.R. Dendroaspis natriuretic peptide and the designer natriuretic peptide, CD-NP, are resistant to proteolytic inactivation. J Mol Cell Cardiol 2011, 51:67-71.
30. Vodovar N., Seronde M.F., Laribi S., et al. Post-translational modifications enhance NT-proBNP and BNP production in acute decompensated heart failure. Eur Heart J 2014, 35:3434-3441.
31. Yandle T., Richards M., Smith M., Charles C., Livesey J., Espiner E. Assay of endopeptidase-24.11 activity in plasma applied to in vivo studies of endopeptidase inhibitors. Clin Chem 1992, 38:1785-1791.
32. Benaglia T., Chauveau D., Hunter D.R., Young D.S. mixtools: an R package for analyzing mixture models. J Stat Softw 2009, 32. Available at:, Accessed June 15, 2015. http://www.jstatsoft.org/v32/i06/.
33. Robin X., Turck N., Hainard A., et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 2011, 12:77.
34. Jessup M. Neprilysin inhibition: a novel therapy for heart failure. N Engl J Med 2014, 371:1062-1064.
35. Pirracchio R., Deye N., Lukaszewicz A.C., et al. Impaired plasma B-type natriuretic peptide clearance in human septic shock. Crit Care Med 2008, 36:2542-2546.
36. von Lueder T.G., Atar D., Krum H. Current role of neprilysin inhibitors in hypertension and heart failure. Pharmacol Ther 2014, 144:41-49.
37. Troughton R., Michael Felker G., Januzzi J.L. Natriuretic peptide-guided heart failure management. Eur Heart J 2014, 35:16-24.